Preclinical Profile and Characterization of the Hepatitis C Virus NS3 Protease Inhibitor Asunaprevir (BMS-650032)Fiona McPhee, Paul M. Scola, Amy K. Sheaffer et al.|Antimicrobial Agents and Chemotherapy|2012Cited by 186
The Discovery of Asunaprevir (BMS-650032), An Orally Efficacious NS3 Protease Inhibitor for the Treatment of Hepatitis C Virus InfectionPaul M. Scola, Jialong Zhu, Li‐Qiang Sun et al.|Journal of Medicinal Chemistry|2014Cited by 112
Discovery and Early Clinical Evaluation of BMS-605339, a Potent and Orally Efficacious Tripeptidic Acylsulfonamide NS3 Protease Inhibitor for the Treatment of Hepatitis C Virus InfectionPaul M. Scola, Fiona McPhee, Alan Xiangdong Wang et al.|Journal of Medicinal Chemistry|2014Cited by 69
Fluorine Substitution Can Block CYP3A4 Metabolism-Dependent Inhibition: Identification of (<i>S</i>)<i>-N</i>-[1-(4-Fluoro-3- morpholin-4-ylphenyl)ethyl]-3- (4-fluorophenyl)acrylamide as an Orally Bioavailable KCNQ2 Opener Devoid of CYP3A4 Metabolism-Dependent InhibitionYong‐Jin Wu, Michael Sinz, Carl D. Davis et al.|Journal of Medicinal Chemistry|2003Cited by 59
( <i>S</i> )- <i>N</i> -[1-(3-Morpholin-4-ylphenyl)ethyl]- 3-phenylacrylamide: An Orally Bioavailable KCNQ2 Opener with Significant Activity in a Cortical Spreading Depression Model of MigraineYong‐Jin Wu, Steven I. Dworetzky, Christopher G. Boissard et al.|Journal of Medicinal Chemistry|2003Cited by 55